Can I please add a note of caution to any list put together. IMO the questions should be of a nature that Paul can realistically and meaningfully answer at the AGM given he doesn't have a crystal ball on the timing of each bureau or how a future funding would be structured.
For example, I'd like Paul to confirm the reason PAR is including BML and biomarkers (ADAMTS-5, COMP) as secondary endpoints in the Phase 3 clinical trial in order to facilitate reimbursement with health insurers based on disease modification. This to be has direct financial implications on future pricing and take-up rates.
A QUESTION OF AGM QUESTIONS, page-12
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |